Role of GLP1-RA in Optimizing Weight Loss Post-Bariatric Surgery: A Systematic Review and Meta-Analysis.
Obes Surg · 2024
Last updated 2026-05-28A review of three clinical trials with 130 patients found that adding GLP1-RA drugs, such as liraglutide at doses of 1.8 to 3 milligrams, helped people lose more weight after bariatric surgery over six months compared to a placebo. The treatment lowered both body mass index (BMI) and the percentage of body weight lost.
AI summary of the abstract below.
| Journal | Obes Surg, 2024 |
|---|---|
| Citations | 11 |
| Relative citation ratio | 2.52 |
| NIH percentile | 80 |
| Molecules | — |
| Conditions studied | Obesity |
Abstract
Bariatric surgery is a widely used intervention for significant weight loss, yet some patients face challenges with insufficient weight loss or weight regain post-surgery. To address this issue, adjunctive treatments like glucagon-like peptide-1 receptor agonists (GLP1-RAs) are being explored for their potential to enhance weight loss outcomes. This meta-analysis was conducted to evaluate the effectiveness of GLP1-RAs in improving weight loss after bariatric surgery compared to a placebo. By systematically reviewing and analyzing data from three randomized controlled trials (RCTs) involving 130 patients, we found that GLP1-RA therapy, particularly liraglutide (1.8-3 mg), significantly reduced mean BMI and body weight percentage at six months. Future studies should explore newer GLP1-RAs with weekly dosing and include longer follow-up periods to assess the durability of these outcomes.
Verbatim abstract via PubMed 39215779 ↗